At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ANVS Annovis Bio, Inc.
Not Yet Opened 04-07 16:00:00 EDT
2.27
-0.08
-3.40%
盘后2.35
+0.08+3.52%
19:58 EDT
High2.41Low2.22Vol647.95K
Open2.33D1 Closing2.35Amplitude8.09%
Mkt Cap64.37MTradable Cap55.07MTotal Shares28.36M
T/O1.49MT/O Rate2.67%Tradable Shares24.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio
TIPRANKS  ·  04-04
Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio
Annovis Bio director Michael B. Hoffman buys $1.5 million common shares
Reuters  ·  04-04
Annovis Bio director Michael B. Hoffman buys $1.5 million common shares
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries
Reuters  ·  04-02
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries
Annovis Publishes Historical Review of Buntanetap in The Scientist
GlobeNewswire  ·  03-31
Annovis Publishes Historical Review of Buntanetap in The Scientist
Annovis Bio Inc - CEO Maria Maccecchini to Serve as Acting CFO Until Replacement Is Identified - SEC Filing
THOMSON REUTERS  ·  03-26
Annovis Bio Inc - CEO Maria Maccecchini to Serve as Acting CFO Until Replacement Is Identified - SEC Filing
Annovis Bio Inc - Mark Guerin Steps Down as CFO Effective March 23, 2026 - SEC Filing
THOMSON REUTERS  ·  03-26
Annovis Bio Inc - Mark Guerin Steps Down as CFO Effective March 23, 2026 - SEC Filing
Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini becomes acting CFO effective March 23, 2026
Reuters  ·  03-26
Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini becomes acting CFO effective March 23, 2026
Annovis Bio enters partnership with NeuroRPM
TIPRANKS  ·  03-19
Annovis Bio enters partnership with NeuroRPM
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial
Reuters  ·  03-19
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study
Reuters  ·  03-19
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study
Neurorpm to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
THOMSON REUTERS  ·  03-19
Neurorpm to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)
TIPRANKS  ·  03-19
Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)
BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
Reuters  ·  03-16
BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
TIPRANKS  ·  03-16
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate
Benzinga  ·  03-16
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate
Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026
THOMSON REUTERS  ·  03-16
Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026
Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Dow Jones  ·  03-16
Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million
Reuters  ·  03-14
Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million
Annovis Bio to Present Twice at AD/PD 2026 International Conference
Reuters  ·  03-03
Annovis Bio to Present Twice at AD/PD 2026 International Conference
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
TIPRANKS  ·  02-21
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating

Introduction

Company Name.
Annovis Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Issue price:
--